2023 Outlook for China’s NRDL

Published on October 27, 2023

The three notable themes with this year’s national reimbursement drug (NRDL) list in China. 

Biopharma stocks in China have reacted to the latest national reimbursement drug list (NRDL) developments with strong gains, signaling a rare vote of confidence in the changes unfolding at this high-stake annual event. 
Three notable themes bode well for new innovative therapies, established NRDL incumbents, rare disease drugs, and pediatric drugs. 

1. Record number of innovative therapies going for this year’s NRDL new inclusion. 

A total of 226 drugs made it to the NRDL long list for new inclusion. Of these 226 drugs, 108 were newly approved in China over the past 12 months—73 of which received approval this year. This underscores the pace of new drug approvals in China and the increasingly important link between regulatory developments and reimbursement.

The most notable candidates for the 2023 NRDL include a number of new drugs…

Continue reading on website
Other news

Unlocking business success with a go to market strategy

October 27, 2023
Launching a new product or expanding into a new market is like sailing uncharted waters. The ship is your product, the crew is your sales team, but what about the map? That's where a go-to-market strategy comes in. This crucial roadmap not only navigates you through complexities but also plays a decisive role in your business success. What is a go to market strategy?A go-to-market strategy is esse

Smarketing unveiled: Boost profits through sales and marketing synergy

October 27, 2023
We’re all aware that the business game has changed. It’s no longer about keeping sales and marketing in their own corners, doing their own thing. In this data-driven era, getting your sales and marketing teams on the same page is more than a nice-to-have – it’s your lifeline. In this article, we’ll dig deep into ‘smarketing’, a not-so-new but seriously underrated strategy for business success. Wha